Close Menu

Drug Discovery & Development

News on drug screening, clinical trials, companion diagnostics, immunotherapy, & personalized therapies in genetics, genomics, and molecular diagnostics.

Adding Verzenio to hormone therapy reduced the risk of relapse by 25 percent, while the PALLAS study, testing another CDK4/6 inhibitor, failed.

The data may result in another option for patients in the crowded first-line ALK-positive lung cancer market, though progression-free survival data are not yet mature.

 

Although the benefit seen in the CAVE study needs Phase III confirmation, the analysis showed that plasma ctDNA testing may help identify best responders.

The MET inhibitor OMO-1 will be studied with Allist's EGFR inhibitor furmonertinib in patients with MET-positive, EGFR-mutated cancers.

The company will use the funds to further develop its proprietary technology for identifying and isolating specific T-cell receptor genes from patients' tumor samples.